Arbutus Biopharma Corp

A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).

ABUS | US

Overview

Corporate Details

ISIN(s):: CA03879J1003 (+2 more)
LEI:
Country:: United States of America
Address:: 701 VETERANS CIRCLE, 18974 WARMINSTER
Website:: https://www.arbutusbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on virology, with a primary mission to develop a functional cure for chronic hepatitis B virus (HBV) infection. The company's strategy centers on developing combination drug regimens that attack the virus through multiple, complementary mechanisms. This multi-pronged approach aims to suppress viral DNA replication, reduce viral antigens (specifically HBsAg), and boost the host's immune response. Its innovative virology portfolio is led by imdusiran, an RNAi therapeutic being investigated as a cornerstone therapy in its HBV clinical studies. Arbutus leverages a team with deep scientific and commercial expertise to advance its pipeline for conditions with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Arbutus Biopharma Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Arbutus Biopharma Corp

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Arbutus Biopharma Corp via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kamada Ltd. Develops specialty plasma-derived therapeutics for rare and serious conditions.	Israel	KMDA
KAMADA LTD Develops specialty plasma-derived therapeutics for rare and serious diseases.	United States of America	KMDA
KANABO GROUP PLC Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.	United Kingdom	KNB
Kancera Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.	Sweden	KAN
KANGSTEM BIOTECH CO., LTD. Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.	South Korea	217730
Karo Pharma AB Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.	Sweden	KARO
Karyopharm Therapeutics Inc. Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.	United States of America	KPTI
KAZIA THERAPEUTICS LTD Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.	United States of America	KZIA
KBIO COMPANY Inc. Using a plant-based platform to rapidly develop biologics for public health.	South Korea	038530
Keeps Biopharma Inc. Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.	South Korea	256940